Showing 1 - 10 of 515
Persistent link: https://www.econbiz.de/10006654861
This paper examines the impact of fiscal incentives on the level of R&D investment. An econometric model of R&D investment is estimated using a new panel of data on tax changes and R&D spending in nine OECD countries over a nineteen year period (1979-1997). We find evidence that tax incentives...
Persistent link: https://www.econbiz.de/10005811382
This paper investigates the relationship between product market competition and innovation. We find strong evidence of an inverted-U relationship using panel data. We develop a model where competition discourages laggard firms from innovating but encourages neck-and-neck firms to innovate....
Persistent link: https://www.econbiz.de/10010859248
Persistent link: https://www.econbiz.de/10007642105
This paper investigates the relationship between product market competition and innovation. We find strong evidence of an inverted-U relationship using panel data. We develop a model where competition discourages laggard firms from innovating but encourages neck-and-neck firms to innovate....
Persistent link: https://www.econbiz.de/10005690870
Increasing product-market competition is believed to be a driving force behind higher productivity. However, even those critics of globalization who accept this argument claim that there is a hard trade-off because tougher competition comes at the price of reducing work—life balance (WLB)....
Persistent link: https://www.econbiz.de/10009439747
Support for many R&D and technology policies relies on empirical evidence that R&D ‘spills over’ between firms. But there are two countervailing R&D spillovers: positive effects from technology spillovers and negative effects from business stealing by product market rivals. We develop a...
Persistent link: https://www.econbiz.de/10009439831
Support for R&D subsidies relies on empirical evidence that R&D "spills over" between firms. But firm performance is affected by two countervailing R&D spillovers: positive effects from technology spillovers and negative business stealing effects from R&D by product market rivals. We develop a...
Persistent link: https://www.econbiz.de/10009439835
This paper examines the arguments for changing the ways that UK drug prices are regulated. In the UK, NHS pharmaceutical expenditures on branded drugs, currently worth about £3 billion a year, have been regulated by the Pharmaceutical Price Regulation Scheme (PPRS) since 1978. We argue that, in...
Persistent link: https://www.econbiz.de/10009440318
CEP's global survey of over 4,000 firms reveals huge variations in the quality of management practices
Persistent link: https://www.econbiz.de/10010884584